Affimed NV (NASDAQ:AFMD)’s share price dropped 0% during mid-day trading on Wednesday . The company traded as low as $2.25 and last traded at $2.50. Approximately 677,694 shares were traded during mid-day trading, a decline of 25% from the average daily volume of 899,755 shares. The stock had previously closed at $2.50.
Separately, Oppenheimer reaffirmed a “hold” rating on shares of Affimed in a research report on Friday, November 24th.
The company has a debt-to-equity ratio of 0.14, a quick ratio of 6.39 and a current ratio of 6.43.
Several large investors have recently bought and sold shares of AFMD. Virtu KCG Holdings LLC purchased a new stake in shares of Affimed in the second quarter valued at about $144,000. Dimensional Fund Advisors LP raised its stake in Affimed by 817.9% during the third quarter. Dimensional Fund Advisors LP now owns 137,783 shares of the biopharmaceutical company’s stock worth $310,000 after purchasing an additional 122,773 shares during the period. Point72 Asset Management L.P. purchased a new position in Affimed during the third quarter worth approximately $658,000. Finally, Nationwide Fund Advisors raised its stake in Affimed by 4.6% during the second quarter. Nationwide Fund Advisors now owns 506,199 shares of the biopharmaceutical company’s stock worth $1,038,000 after purchasing an additional 22,172 shares during the period. Hedge funds and other institutional investors own 40.35% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Affimed (AFMD) Trading Down 0%” was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://sportsperspectives.com/2018/02/09/affimed-afmd-trading-down-0.html.
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.